子宫内膜样子宫内膜癌的复发与生存:一项基于人群的队列研究
这项基于瑞典妇科癌症质量登记库的区域人群队列纳入2010至2017年初次手术的1630例子宫内膜样子宫内膜癌患者,136例(8.3%)复发,中位复发时间22.5个月;5年总生存率88.0%,无病生存率83.9%,仅阴道复发者5年总生存率77.0%,其他部位复发者36.1%。多变量分析显示年龄、FIGO III期和辅助治疗是复发的独立预后因素。
要点
- 子宫内膜样子宫内膜癌总体复发率较低(8.3%),仅阴道复发者生存预后较好。
- 5年总生存率88.0%,无病生存率83.9%,未复发者总生存率91.9%。
- 年龄、FIGO III期和辅助治疗是复发的独立预后因素。
核心结论
- 子宫内膜样子宫内膜癌总体复发率低,小部分为仅阴道复发且生存良好,其他部位复发预后差;年龄、FIGO III期和辅助治疗是复发的独立预后因素。
研究设计与样本
- 基于瑞典妇科癌症质量登记库(SQRGC)的区域人群队列研究,纳入2010至2017年初次手术的子宫内膜样子宫内膜癌女性,共1630例,从登记库获取患者特征和结局并通过病历复核补充。
主要发现
- 1630例中136例(8.3%)复发,中位复发时间22.5个月(范围3.2-59.3)。
- 69.1%诊断时为单一部位复发,27.2%仅为阴道复发。
- 总5年总生存率88.0%(95%CI:86.4-89.7),5年净生存率98.6%(95%CI:96.5-100.7)。
- 未复发者5年总生存率91.9%(95%CI:90.4-93.3),5年净生存率102.8%(95%CI:100.9-104.8)。
- 仅阴道复发者5年总生存率77.0%(95%CI:64.0-92.6),其他所有复发者为36.1%(95%CI:27.5-47.3);总5年无病生存率83.9%(95%CI:82.0-85.7)。
关键数值与推荐
- 多变量分析中,年龄的复发HR为1.29(95%CI:1.11-1.51;p=0.001)。
- FIGO III期的复发HR为2.78(95%CI:1.80-4.29;p<0.001)。
- 辅助治疗的复发HR为1.84(95%CI:1.22-2.78;p=0.004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate recurrences and survival in endometrioid endometrial cancer (EC) in a complete population-based cohort. METHODS: A regional population-based study including women with endometrioid EC, identified by the Swedish Quality Registry for Gynecological Cancer (SQRGC), where primary surgery was performed between 2010 and 2017. Patient characteristics and outcomes, including recurrences, were retrieved from the SQRGC and completed by records reviews. Overall (OS), net (NS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method. The Fine and Gray proportional subdistribution hazards' regression model was used for risk factors for recurrence. RESULTS: There were 1630 women included in the study, whereof 136 (8.3%) had a recurrence with a median time to recurrence of 22.5 months (range 3.2-59.3). One site of recurrence was diagnosed in 69.1%, while 27.2% being only vaginal. The total 5-year OS was 88.0%(95% CI:86.4-89.7) and the 5-year NS 98.6%(95% CI:96.5-100.7). If no recurrence occurred, the OS was 91.9%(95% CI:90.4-93.3) and NS 102.8%(95% CI:100.9-104.8). For only vaginal recurrence, 5-year OS was 77.0%(95% CI:64.0-92.6) compared to 36.1%(95% CI:27.5-47.3) for all other recurrences. The total 5-year DFS was 83.9%(95% CI:82.0-85.7). In the multivariable analysis, age, FIGO stage and primary treatment were found independent factors for recurrence with a HR of 1.29(95% CI:1.11-1.51;p = 0.001) for age, 2.78(95% CI:1.80-4.29;p < 0.001) for FIGO stage III and 1.84(95% CI:1.22-2.78;p 0.004) for adjuvant treatment. CONCLUSION: There is an overall low recurrence rate for endometrioid ECs with a minor portion being only vaginal, associated with a favorable survival in contrast to other recurrences with a poor prognosis. Age, FIGO stage III and adjuvant treatment were found independent prognostic factors for recurrence.
引用
- Åkesson Å, Adok C, Dahm-Kähler P, et al. Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study. Gynecol Oncol. 2022. PMID: 36434947. doi:10.1016/j.ygyno.2022.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。